Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE®

Tuesday 25 June 2019


SAN DIEGO, June 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center (VRC), part of the National Institutes of Health, enabling the VRC's use of Halozyme's ENHANZE® drug delivery technology to develop subcutaneous formulations of broadly neutralizing antibodies (bnAbs) against HIV for HIV treatment.

The two bnAbs selected for the CRADA are VRC07-523LS and N6LS. The VRC will engage in early phase studies in healthy adults investigating the safety, tolerability, dose, and pharmacokinetics of formulating these bnAbs with ENHANZE® for the purpose of optimizing subcutaneous administration of these antibodies.

"We are excited to collaborate with NIAID as they seek to develop new therapies that potentially address a large unmet need in the field of HIV treatment and prevention," said Dr. Helen Torley, President and CEO of Halozyme. "This CRADA is an example of the value ENHANZE® can potentially bring to the treatment of infectious diseases, particularly in the early stages of development."